Cargando…

Impact of X-Linked Hypophosphatemia on Muscle Symptoms

X-linked hypophosphatemia (XLH) is the most common hereditary form of rickets and deficiency of renal tubular phosphate transport in humans. XLH is caused by the inactivation of mutations within the phosphate-regulating endopeptidase homolog X-linked (PHEX) gene and follows an X-dominant transmissio...

Descripción completa

Detalles Bibliográficos
Autores principales: Romagnoli, Cecilia, Iantomasi, Teresa, Brandi, Maria Luisa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9778127/
https://www.ncbi.nlm.nih.gov/pubmed/36553684
http://dx.doi.org/10.3390/genes13122415
_version_ 1784856280751407104
author Romagnoli, Cecilia
Iantomasi, Teresa
Brandi, Maria Luisa
author_facet Romagnoli, Cecilia
Iantomasi, Teresa
Brandi, Maria Luisa
author_sort Romagnoli, Cecilia
collection PubMed
description X-linked hypophosphatemia (XLH) is the most common hereditary form of rickets and deficiency of renal tubular phosphate transport in humans. XLH is caused by the inactivation of mutations within the phosphate-regulating endopeptidase homolog X-linked (PHEX) gene and follows an X-dominant transmission. It has an estimated frequency of 1 case per 20,000, and over 300 distinct pathogenic variations have been reported that result in an excess of fibroblast growth factor 23 (FGF23) in the serum. Increased levels of FGF23 lead to renal phosphate loss, decreased serum 1,25-dihydroxyvitamin D, and increased metabolism of 1,25-dihydoxyvitamin D, resulting in hypophosphatemia. Major clinical manifestations include rickets, bone deformities, and growth retardation that develop during childhood, and osteomalacia-related fractures or pseudo-fractures, degenerative osteoarthritis, enthesopathy, dental anomalies, and hearing loss during adulthood, which can affect quality of life. In addition, fatigue is also a common symptom in patients with XLH, who experience decreased motion, muscle weakness, and pain, contributing to altered quality of life. The clinical and biomedical characteristics of XLH are extensively defined in bone tissue since skeletal deformations and mineralization defects are the most evident effects of high FGF23 and low serum phosphate levels. However, despite the muscular symptoms that XLH causes, very few reports are available on the effects of FGF23 and phosphate in muscle tissue. Given the close relationship between bones and skeletal muscles, studying the effects of FGF23 and phosphate on muscle could provide additional opportunities to understand the interactions between these two important compartments of the body. By describing the current literature on XLH and skeletal muscle dysfunctions, the purpose of this review is to highlight future areas of research that could contribute to a better understanding of XLH muscular disability and its management.
format Online
Article
Text
id pubmed-9778127
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-97781272022-12-23 Impact of X-Linked Hypophosphatemia on Muscle Symptoms Romagnoli, Cecilia Iantomasi, Teresa Brandi, Maria Luisa Genes (Basel) Review X-linked hypophosphatemia (XLH) is the most common hereditary form of rickets and deficiency of renal tubular phosphate transport in humans. XLH is caused by the inactivation of mutations within the phosphate-regulating endopeptidase homolog X-linked (PHEX) gene and follows an X-dominant transmission. It has an estimated frequency of 1 case per 20,000, and over 300 distinct pathogenic variations have been reported that result in an excess of fibroblast growth factor 23 (FGF23) in the serum. Increased levels of FGF23 lead to renal phosphate loss, decreased serum 1,25-dihydroxyvitamin D, and increased metabolism of 1,25-dihydoxyvitamin D, resulting in hypophosphatemia. Major clinical manifestations include rickets, bone deformities, and growth retardation that develop during childhood, and osteomalacia-related fractures or pseudo-fractures, degenerative osteoarthritis, enthesopathy, dental anomalies, and hearing loss during adulthood, which can affect quality of life. In addition, fatigue is also a common symptom in patients with XLH, who experience decreased motion, muscle weakness, and pain, contributing to altered quality of life. The clinical and biomedical characteristics of XLH are extensively defined in bone tissue since skeletal deformations and mineralization defects are the most evident effects of high FGF23 and low serum phosphate levels. However, despite the muscular symptoms that XLH causes, very few reports are available on the effects of FGF23 and phosphate in muscle tissue. Given the close relationship between bones and skeletal muscles, studying the effects of FGF23 and phosphate on muscle could provide additional opportunities to understand the interactions between these two important compartments of the body. By describing the current literature on XLH and skeletal muscle dysfunctions, the purpose of this review is to highlight future areas of research that could contribute to a better understanding of XLH muscular disability and its management. MDPI 2022-12-19 /pmc/articles/PMC9778127/ /pubmed/36553684 http://dx.doi.org/10.3390/genes13122415 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Romagnoli, Cecilia
Iantomasi, Teresa
Brandi, Maria Luisa
Impact of X-Linked Hypophosphatemia on Muscle Symptoms
title Impact of X-Linked Hypophosphatemia on Muscle Symptoms
title_full Impact of X-Linked Hypophosphatemia on Muscle Symptoms
title_fullStr Impact of X-Linked Hypophosphatemia on Muscle Symptoms
title_full_unstemmed Impact of X-Linked Hypophosphatemia on Muscle Symptoms
title_short Impact of X-Linked Hypophosphatemia on Muscle Symptoms
title_sort impact of x-linked hypophosphatemia on muscle symptoms
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9778127/
https://www.ncbi.nlm.nih.gov/pubmed/36553684
http://dx.doi.org/10.3390/genes13122415
work_keys_str_mv AT romagnolicecilia impactofxlinkedhypophosphatemiaonmusclesymptoms
AT iantomasiteresa impactofxlinkedhypophosphatemiaonmusclesymptoms
AT brandimarialuisa impactofxlinkedhypophosphatemiaonmusclesymptoms